Inoperable Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)Phase 1/2NCT04086485Papers
Lu-177-DOTATATE
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
4 Phase 1 studies recruiting right now, most recently updated first.
Open the Phase 2 page · a list of only those studies
Triangle is made by Triangle Health, Inc.
Thyroid and neuroendocrine4 studies
Inoperable Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)Phase 1/2NCT04086485Papers
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
BRAF V600E Wild-Type Anaplastic Thyroid CancerPhase 1NCT06902376
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
Recurrent Differentiated Thyroid CancerPhase 1NCT04892303
Combination Radiotherapy and Radiopharmaceutical Therapy Treatment Planning for Thyroid Cancer
Neuroendocrine CarcinomaPhase 1NCT06889493
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)